Scientists at Umeå University have created an experimental antibody drug that halts tumor growth and prevents metastasis in aggressive prostate cancer, marking a significant advance in treating one of the most common cancers in men.
The findings, published in Signal Transduction and Targeted Therapy, demonstrate that the fully human antibody successfully stopped both tumor expansion and metastatic spread in preclinical studies of aggressive prostate cancer. Because it is constructed entirely from human proteins, the treatment is well-suited for pharmaceutical development and may carry lower risk of side effects compared to other approaches.
Maréne Landström, a pathology professor who led the research at Umeå University's Department of Medical Biosciences, emphasized the breakthrough in understanding what drives cancer progression. "We have been able to identify the mechanisms that drive cancer cell growth, invasiveness, and metastatic spread," she said.
Prostate cancer ranks among the most frequently diagnosed cancers in men, yet the disease varies dramatically in its behavior. While many tumors grow slowly and pose little threat to life, some cases turn aggressive and spread beyond the prostate to lymph nodes and bones. The new antibody targets this dangerous form specifically.
The path from laboratory success to patient treatment remains lengthy. Landström cautioned that additional safety studies must be completed and regulatory approval from European or American authorities will be required before the drug can reach patients. "This is a promising step forward, but several important stages remain," she said.
The antibody development relied on collaboration across multiple institutions and funding sources. The SciLifeLab Drug Discovery and Development Platform contributed essential drug development expertise, while the Umeå Biotech Incubator and funding from MetaCurUm Biotech AB, a local biotechnology company, supported the research efforts. The work also received backing from the Knut and Alice Wallenberg Foundation, the Erling Persson Foundation, the Kempe Foundations, and several Swedish research councils and cancer organizations.
Researchers now plan to test whether the same antibody strategy could be effective against other solid tumors. Landström indicated that expanding the approach beyond prostate cancer could lead to a broader class of cancer treatments. "We hope that our work will ultimately contribute to the development of a new cancer drug that can benefit patients," she said.
Author Jessica Williams: "A fully human antibody that actually stops metastasis in preclinical work deserves attention, though the years ahead of testing will separate real promise from hype."
Comments